Fig. 6.
Fig. 6. Detection of CD11c− IL-3R+DCs in FL-treated but not placebo-treated individuals. / (A) PBMCs from FL-treated (100 μg · kg−1 · d−1) or placebo-treated individuals (day 15) were analyzed by flow cytometry for large (FSChigh) CD11c− cells (shown gated) or cells that lacked the mature lineage markers CD3, CD14, CD19, and CD56 but expressed high levels of IL-3Rα. (B) Expression of CD1b/c, CD2, CD4, CD40, CD45RA, CD80, CD86, and HLA-DR on CD11c− IL-3Rα+ PBMCs from an FL-treated individual. Results are representative of 4 separate experiments.

Detection of CD11c− IL-3R+DCs in FL-treated but not placebo-treated individuals.

(A) PBMCs from FL-treated (100 μg · kg−1 · d−1) or placebo-treated individuals (day 15) were analyzed by flow cytometry for large (FSChigh) CD11c− cells (shown gated) or cells that lacked the mature lineage markers CD3, CD14, CD19, and CD56 but expressed high levels of IL-3Rα. (B) Expression of CD1b/c, CD2, CD4, CD40, CD45RA, CD80, CD86, and HLA-DR on CD11c− IL-3Rα+ PBMCs from an FL-treated individual. Results are representative of 4 separate experiments.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal